SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-21-205559
Filing Date
2021-07-01
Accepted
2021-07-01 07:29:03
Documents
12
Period of Report
2021-07-01
Items
Item 1.01: Entry into a Material Definitive Agreement

Document Format Files

Seq Description Document Type Size
1 8-K d33771d8k.htm   iXBRL 8-K 28928
  Complete submission text file 0001193125-21-205559.txt   149102

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA mcrb-20210701.xsd EX-101.SCH 2906
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE mcrb-20210701_lab.xml EX-101.LAB 17373
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE mcrb-20210701_pre.xml EX-101.PRE 10962
5 EXTRACTED XBRL INSTANCE DOCUMENT d33771d8k_htm.xml XML 3234
Mailing Address 200 SIDNEY STREET CAMBRIDGE MA 02139
Business Address 200 SIDNEY STREET CAMBRIDGE MA 02139 617 945 9626
Seres Therapeutics, Inc. (Filer) CIK: 0001609809 (see all company filings)

IRS No.: 274326290 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37465 | Film No.: 211064046
SIC: 2834 Pharmaceutical Preparations